CO-JOHNS-MANVILLE
17.6.2020 19:32:07 CEST | Business Wire | Press release
Johns Manville (JM), a global building and specialty products manufacturer and a Berkshire Hathaway company, announced today that Bob Wamboldt will become President and CEO on Sept. 1, 2020. Mary Rhinehart, the company’s current Chairman, President and CEO, will retain the role of Chairman.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005674/en/
Wamboldt joined Johns Manville in 2003 and became President of JM’s Insulation Systems business in February 2017. He earlier led the Engineered Products North America and Roofing Systems businesses at JM. Wamboldt is also Chairman of the North American Insulation Manufacturers Association and previously served as president of the Asphalt Roofing Manufacturers Association.
“I have been privileged to lead each of our businesses and learn first-hand the strength of the Johns Manville customer relationships, products, technologies and people,” Wamboldt said. “I look forward to working with the JM team and our customers to make the company even stronger in the global markets we serve. I also want to thank Mary for her leadership and guidance over the years and know I will benefit from her continued support as Chairman.”
Before joining Johns Manville, Wamboldt worked 16 years at PPG Industries Inc., where he held a variety of positions in the company’s Fiber Glass and Coatings divisions. He earned a bachelor’s degree in chemistry from Lehigh University. He and his wife live in Denver.
Rhinehart became Johns Manville’s President and CEO in 2012 and assumed the additional role of Chairman in 2014. Before becoming President and CEO, she was the company’s Chief Financial Officer for eight years. During her more than 40 years with Johns Manville, she also held leadership roles in treasury, supply chain, M&A and human resources, and she managed several of the company’s business units.
“I am immensely proud of JM’s employees and all we have accomplished together,” Rhinehart said. “Johns Manville is an important part of my life, and its continued success is my top priority as we transition to new leadership. I am pleased to hand the company over to such an accomplished JM executive as Bob and am confident he and our 8,000 employees around the world will continue to build on JM’s 162-year track record of success.”
Johns Manville became a Berkshire Hathaway company in February 2001.
“Bob’s business acumen, broad base of experience, and extensive industry knowledge make him the natural successor to Mary as CEO,” said Greg Abel, Berkshire Hathaway’s Vice Chairman. “I also want to extend my gratitude to Mary for her dedication and commitment to JM over her entire career. Under her leadership as CEO, JM delivered exceptional performance, successfully expanded its market presence, and made sound, strategic investments to position the company for success well into the future.”
Warren Buffett, Chairman and CEO of Berkshire Hathaway, added: “Mary was everything we had hoped to find in a CEO.”
About Johns Manville
Johns Manville, a Berkshire Hathaway company (NYSE: BRK.A, BRK.B), is a leading manufacturer and marketer of premium-quality building and specialty products. In business since 1858, the Denver-based company has annual sales over $3 billion and holds leadership positions in all of the key markets that it serves. Johns Manville employs 8,000 people and operates 46 manufacturing facilities in North America, Europe and China. Additional information can be found at www.jm.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005674/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 08:30:00 CEST | Press release
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-
Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes12.5.2026 08:00:00 CEST | Press release
Merz Therapeutics to present 11 abstracts at ISPRM World Congress 2026, highlighting its commitment to improving outcomes for people living with movement disorders Updated analysis indicates that optimizing botulinum toxin dosing over multiple injection cycles may be an important factor in improving outcomes in people living with limb spasticity, with available clinical data suggesting support for flexible, individualized dosing with incobotulinumtoxinA (XEOMIN®) Updated meta-analyses examining secondary treatment failure and neutralizing antibodies suggest a potential for sustained long-term treatment response with incobotulinumtoxinA (XEOMIN®) Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced it will present 11 scientific abstracts at the International Society of Physical and Rehabilitation Medicine (ISPRM) 2026 World Congress. Taking place from May 17th to May 21st in Vancouver, Canada, the presentations will feature key data on optimal dosin
SES Delivers Robust Q1 2026 Results & Reiterates Full-Year Outlook12.5.2026 07:30:00 CEST | Press release
SES S.A. announces financial results for the three months ended 31 March 2026. Q1 2026 Performance (€ million) Q1 2026 as reported (1) Q1 2025 as reported (1) ∆ At constant FX (2) Q1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.18 1.04 1.04 Revenue 847 509 +80.5% 909 +3.1% Adjusted EBITDA (4) 404 280 +57.0% 425 +5.0% 1) ‘Reported basis’ with Intelsat fully consolidated from 17 July 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralise currency variations 3) ‘Like-for-like basis’ is as if Intelsat fully consolidated from 1 January 2024 4) Excluding operating expenses/income recognised in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) Networks revenue up +106.0% yoy(1) supported by growth in Mobility (+207.8% yoy(1); including positive impact from a contract restructuring in Aviation) and Gov
GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI12.5.2026 03:00:00 CEST | Press release
GIGABYTE Technology, a global leader in high-performance computing, is taking its most comprehensive end-to-end portfolio for AI infrastructure to COMPUTEX 2026 under the theme "Future Landing." As AI transitions from training into large-scale inference and real-world operation, GIGABYTE addresses the industry's most pressing challenge: not whether AI can be built, but how quickly and reliably it can be deployed, operated, and sustained at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505299592/en/ GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI At COMPUTEX, GIGABYTE organizes its showcase around three states that define the lifecycle of production AI infrastructure. Ready: integrated systems that have been fully built, simulated, validated, and prepared for deployment. Deployable: modular clusters engineered for rapid implementation across diverse environments.
INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering11.5.2026 21:49:00 CEST | Press release
INNIO Group ("INNIO"), a leading global distributed energy solutions provider, today announces that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511389675/en/ INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. INNIO has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "INIO." Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. BofA Securities, Barclays and Citigroup are acting as book-running managers for the proposed offering. Baird, BNP Paribas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom